{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011765","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.213332+00:00","generated_at":"2026-05-17T16:04:51.866510+00:00","sec_items":["7.01","2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Elite Pharmaceuticals announces Q1 FY2026 results release on Aug 14, conference call Aug 15","bullets":["Financial results for Q1 FY2026 (ended June 30, 2025) to be released August 14, 2025.","Conference call to discuss results and provide corporate update on August 15, 2025 at 11:30 AM EDT.","Dial-in: 1-800-346-7359 (domestic) or 1-973-528-0008 (intl), conference ID 98840.","Stockholders can submit questions by email to dianne@elitepharma.com by deadlines: general by Aug 13, financial by Aug 14."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011765","json":"https://secwatch.observer/filing/0001493152-25-011765.json","markdown":"https://secwatch.observer/filing/0001493152-25-011765.md","text":"https://secwatch.observer/filing/0001493152-25-011765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315225011765/0001493152-25-011765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315225011765/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:04:51.866510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}